32 search results for: disease background

expert video

Etiology and Diagnosis of Bullous Pemphigoid

2 min

Dermatology

Professor Joost Meijer discusses the complex etiology and diagnosis of BP

interactivity

Diagnosis of Bullous Pemphigoid Interactive Patient Case

10 min

Dermatology

An interactive patient case tool involving a deeper dive into assessing clinical presentation when diagnosing bullous pemphigoid (BP).

Infographic

The Role of Mast Cells, Basophils, and Type 2 Cells and Cytokines in CSU

5 min

Dermatology

The pathophysiology of chronic spontaneous urticaria (CSU) is complex and involves mast cell degranulation and elements of type 2 inflammation. Learn more about the role of mast cells, basophils, and type 2 inflammatory cells and cytokines involved in the pathophysiology of CSU.

expert video

Type 2 Inflammation and Neuroimmune Axis Dysregulation in AD, PN, and CSU

3 min

Dermatology

Examination of the unique ways type 2 inflammation contributes to itch in AD, PN, and CSU.

expert video

Atopic Dermatitis as a Risk Factor for the Development of Food Allergies

2 min

Dermatology

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Leo, MD discusses the role of atopic dermatitis as a risk factor for developing food allergies.

Infographic

Bullous Pemphigoid (BP) Pathophysiology Infographic

4 min

Dermatology

A static infographic detailing how autoimmunity and Type 2 inflammation play a critical role in the pathophysiology of Bullous Pemphigoid (BP).

Podcast

ADVENT On Air | Getting to Grips With Atopic Hand and Foot Dermatitis: What Is It, and What Does It Mean for Patients?

20 min

Dermatology

This podcast episode looks at the epidemiology, clinical presentation and classification of atopic dermatitis of the hand and feet and the impact it has on patients' quality of life.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region